Search
Galiximab
go.drugbank.com/drugs/DB04901InvestigationalGaliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
Talnetant
go.drugbank.com/drugs/DB06429InvestigationalTalnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential
Edodekin alfa
go.drugbank.com/drugs/DB15631Investigationalinvestigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or Cannot Be Removed by
IDM-1
go.drugbank.com/drugs/DB05292ExperimentalIt is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.
Glucose-6-Phosphate
go.drugbank.com/drugs/DB03581ExperimentalAn ester of glucose with phosphoric acid, made in the course of glucose metabolism by mammalian and other cells.
(S)-Warfarin
go.drugbank.com/drugs/DB14055InvestigationalWarfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways.
Jaktinib
go.drugbank.com/drugs/DB17545InvestigationalJaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals.
ARC183
go.drugbank.com/drugs/DB05124ExperimentalARC183 is a DNA aptamer, which is a single-stranded DNA molecule consisting of 15 deoxynucleotides that forms well-defined three-dimensional configuration, allowing it to bind to thrombin with high affinity … The key advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life, giving it the potential to be an ideal agent for medical procedures that require rapid
Giroctocogene fitelparvovec
go.drugbank.com/drugs/DB16174InvestigationalGiroctocogene fitelparvovec is under investigation in clinical trial NCT04370054 (Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia a Adults).
BLX-883
go.drugbank.com/drugs/DB05904InvestigationalBLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C.